Skip to main content
Publications
Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, FlieBer-Gorzer E, Gelsinger C, Hanusch U, Ludvik B, Maca T, Schober A, Sock R, Speidl WS, Stulnig TM, Weitgasser R, Zirlik A, Koch M, Wienerroither S, Wolowacz SE, Diamand F, Catapano AL. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Wein Klin Wochenschr. 2023 Jul;135(13-14):364-74. doi: 10.1007/s00508-023-02221-4
Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME. Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S349. doi: 10.1016/j.jval.2023.03.2378
Forns J, Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C. Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study. Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y
Rebordosa C, Farkas DK, Montonen J, Laugesen K, Voss F, Aguado J, Bothner U, Rothman KJ, Zint K, Mines DI, Ehrenstein V. Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):827-39. doi: 10.1002/pds.5432
Zografos L, Calingaert B, Wolin D, Andrews E, Davis K, Nelson K, Lenz Y, Tarenz C, Horvat-Broecker A, Suzart-Woischnik K. Evaluating physician knowledge of risks and safe use of rivaroxaban. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Forns J, Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Reutfors J, Rebordosa C. Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments. Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Fortuny J, Gilsenan AW, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J, Flynn RW, Plana E, Ziemiecki R, Andrews EB, Gilsenan A. Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-7. doi: 10.1097/QAI.0000000000002075
Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447
Lewis EF, Coles TM, Lewis S, Nelson LM, Barrett A, DeMuro Romano C, Stull DE, Turner SJ, Chang CG. Development, psychometric evaluation, and initial feasibility assessment of a symptom tracker for use by patients with heart failure (HFaST). J Patient Rep Outcomes. 2019 May 2;3(1):26. doi: 10.1186/s41687-019-0113-6
Castellsague J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B, Bui C, Arana A, Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthann S. Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):953-61. doi: 10.1002/pds.4584
Cainzos-Achirica M, Rebordosa C, Vela E, Cleries M, Matsushita K, Plana E, Rivero-Ferrer E, Enjuanes C, Jimenez-Marrero S, Garcia-Rodriguez LA, Comin-Colet J, Perez-Gutthann S. Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. Am Heart J. 2018 Aug;202:76-83. doi: 10.1016/j.ahj.2018.05.005
Cainzos-Achirica M, Varas-Lorenzo C, Pottegard A, Asmar J, Plana E, Rasmussen L, Bizouard G, Forns J, Hellfritzsch M, Zint K, Perez-Gutthann S, Pladevall-Vila M. Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: a case study of dabigatran etexilate in Europe. Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):713-23. doi: 10.1002/pds.4416
Gilsenan A, Fortuny J, Plana E, Ruigomez A, Karlsson P, Flynn RWV, Cantero OF, Garcia-Rodriguez L, Linner L, Cainzos-Achirica M, Bartsch J, MacDonald T, Kieler H, Andrews EB. Non-interventional cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort initiating polyethylene glycol 3350 (PEG). Poster presented at the 2018 Digestive Disease Week; June 3, 2018. Washington, DC.
